Tertiary Lymphoid Structure and CD8 T Cell Exclusion in Minimally Invasive Adenocarcinoma

Jin Wang[1], Dongbo Jiang[2], Xiaoqi Zheng[3], Wang Li[4], Tian Zhao[4], Di Wang[5], Huansha Yu[5], Dongqing Sun[1], Ziyi Li[1], Jian Zhang[6], Zhe Zhang[7], Likun Hou[5], Gening Jiang[8], Fan Zhang[4], Kun Yang[2], Peng Zhang[8]

Affiliation

1. Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
2. Department of Immunology, School of Basic Medicine, Air-Force Medical University. Xi'an, China.
3. Department of Mathematics, Shanghai Normal University, Shanghai, China.
4. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Life Sciences and Technology, Shanghai, China.
5. Tissue Bank, Department of Pathology, Experimental Animal Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
6. Academy of Medical Engineering and Translational Medicine, Tianjin University, China
7. Department of Gynecologic Oncology, Chinese PLA General Hospital, Beijing, China
8. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Abstract

Lung adenocarcinoma is the leading cause of cancer death. To characterize the tumor microenvironment (TME) of early-stage lung adenocarcinoma, we performed RNA-seq profiling on 59 pairs of minimally invasive adenocarcinoma (MIA) tumors and matched adjacent normal lung tissues from Chinese patients. We observed mucin over-expression and glycosylation, and altered cytokine-cytokine interactions in MIA tumors, which also had distinct adaptive immune TME of higher CD4+ T cell infiltration, higher plasma B cell activation, and lower CD8+ T cell infiltration. The high expression of markers for B cells, activated CD4 T cells, and follicular helper T (Tfh) cells in MIA implicated the formation of tertiary lymphoid structures (TLS), which were supported by two independent single-cell RNA-seq data. Multiplex immunohistochemistry (mIHC) staining of 22 MIA tumors validated TLS formation and revealed an enrichment of follicular regulatory T cells (Tfr) in TLS follicles, which may explain the lower CD8+ T cell infiltration and attenuated anti-tumor immunity in MIA.

Significance: We discovered a potential immunosuppressive phenotype in MIA mediated by follicular regulatory T cells (Tfr) in TLS formation, which could be a potential mechanism of CD8+ T cell exclusion. Our study demonstrated how integrating tumor transcriptome and pathology can characterize the TME and elucidate potential mechanisms of tumor immune evasion.

Introduction

Lung cancer is the world's second-most common cancer but is by far the leading cause of cancer death. While most early lung cancer cases can be successfully treated, many lung cancers are not diagnosed until symptoms appear, at which time the disease has progressed to a more advanced stage. In recent years, low-dose computed tomography (LDCT) scan has been used for early lung cancer detection on people with a higher risk of lung cancer. Although LDCT has been shown to decrease the rate of lung cancer death, it also has a ~20% false-positive detection rate and exposes people to low-dose radiation (1). While these imaging approaches are promising, early detection and treatment of lung cancer might be complemented by molecular approaches that characterize pre-cancerous lesions and their surrounding microenvironment. To better characterize the molecular, cellular, and tissue changes that drive tumor development and progression in its earliest stages, National Cancer Institute of the United States has recently issued new initiatives to construct an atlas of pre-cancer lesions and their surrounding microenvironment. Following The Cancer Genome Atlas (TCGA) project which successfully profiled thousands of human cancers, this new effort promises to provide better understanding of cancer initiation and bring new strategies for cancer diagnosis and treatment.

Non-Small Cell Lung Cancer (NSCLC) accounts for about 80% of all lung cancer incidences, with a majority belonging to the adenocarcinoma subtype. Early lung adenocarcinoma development is believed to progress from adenocarcinoma in situ, to minimally invasive adenocarcinoma (MIA), then to fully invasive adenocarcinoma (2). Despite the difficulty of diagnosing early lung cancer lesions and obtaining samples, there have been a number of genomics studies on early lung cancers in recent years (2-5). For example, one study examined the mutation patterns of in situ and invasive adenocarcinoma by whole-exome sequencing and compared the results with TCGA (2). Another study used targeted sequencing and droplet PCR to examine the mutation patterns in both early tumors and the matched blood samples (3). Most of these studies focused on identifying driver mutations potentially responsible for tumor initiation, which have been summarized in a recent review (6).

Besides tumor mutations, there has been growing appreciations of the important roles tumor microenvironment (TME) plays in cancer development, progression, and outcome. The TME consists of cancer cells, tumor-infiltrating lymphocytes, stromal and vascular cells, along with extra-cellular molecules such as cytokines and chemokines that modulate their interactions. Changes in cellular and extra-cellular components of the TME can facilitate tumor behaviors such as unchecked tumor growth and immune evasion (7). To examine such TME changes, gene expression profiles from RNA-seq are more informative than DNA-based tumor profiling.

Besides characterizing differentially expressed genes and pathways, RNA-seq has
reasonable power to detect somatic mutations (8), gene fusions (9) and microsatellite
instability (10) , especially if matched normal samples are also available. There have also been
multiple studies that use tumor RNA-seq data to infer immune cell populations and subtypes,
and to associate immune infiltration with clinical outcomes or driver mutations (11,12).
However, few such tumor profiling studies include matched adjacent tissues, and often the
normal samples are sequenced at much lower coverage. One NSCLC study, which combined
Whole Exome Sequencing (WES) and RNA-seq to discover the association between EGFR
mutation and tumor-infiltrating B lymphocytes, did not profile RNA-seq from the matched
normal, thus limiting the ability to characterize tumor-normal differences (13). Therefore,
knowledge of the tumor immune microenvironment in early lung cancer patients, especially in
comparison with the matched adjacent tissues, remains lacking.

In the TME, B cells and T cells are able to recognize and bind tumor antigens to induce
adaptive immune responses (14,15). How cytotoxic T lymphocytes (CTL) influence immune
response to tumor progression has been under intensive investigation in recent years (16).
However, the role of B-T cell interactions in anti-tumor immune response has not been
completely understood. Inflammation is known to be a potential cause and hallmark of early
cancer development (17), and clusters of B and T lymphocytes can form tertiary lymphoid
structure (TLS) at the site of inflammation(18). There has been increasing research interest in
understanding TLS formation and function in human pathology, especially related to clinical
implications and potential therapeutic targeting (19). A recent review summarized studies on
the presence, composition, and functions of TLS in cancers and how TLS is correlated with
therapeutic response (20). Three recent studies also reported TLS formation to be associated
with response to immune checkpoint blockade (21-24). However, the impact of immune-
stimulating or immune-suppressive components of TLS on tumor progression or immune
evasion still awaits elucidation. Therefore, investigating TLS formation and its consequences
on the tumor immune microenvironment in early stage tumors has the potential to inform
disease etiology, precision medicine, and clinical prognosis.

In this study, we sought to characterize the TME of 59 pairs of minimally invasive
adenocarcinoma (MIA) tumors and their matched adjacent normal tissues using RNA-seq.
These tumors were initially diagnosed with LDCT, then surgically resected and confirmed for
MIA by pathologists using hematoxylin and eosin (H&E) staining. To ensure an unbiased
comparison between tumor and normal, we sequenced the RNA of both tumor and normal at
higher depth than TCGA. This allowed us not only to examine the gene expression changes
and infer immune cell infiltration levels, but also to compare the clonal expansion patterns of

the immune receptor repertoires between the tumors and the matched normal tissues.

Furthermore, by combining transcriptome data, H&E staining, and multiplex

immunohistochemistry (mIHC) staining on paraffin sections, we confirmed the TLS formation

in the MIA TME, which might be associated with immune suppression and tumor initiation.

These data and results provide insights into the etiology of early lung adenocarcinoma, which

may inform immunotherapy treatment strategies for lung cancers.

Results

Genes in cytokine-cytokine receptor interactions and mucin glycosylation are over expressed in MIA

We collected 59 pairs of pathology-confirmed MIA tumors and matched adjacent normal tissues **(Fig. S1, Table S1)**. All the MIA tumors were confirmed by pathology using the 2015 World Health Organization classification criteria of lung tumors (25). Hematoxylin and eosin (H&E) staining confirmed the tumor lepidic growth pattern and the less than 5 mm in diameter of invasive components **(Figure 1A)**. We conduced RNA-seq of all the samples at a minimum depth of 100 million paired-end 150bp fragments, roughly three times the sequencing depth of TCGA samples. We mapped the RNA-seq reads with STAR (26), quantified gene expression with HTSeq (27), and called differentially expressed genes between paired tumor and normal samples using edgeR (28). In total, we identified 1,471 up-regulated and 431 down-regulated genes with over 2-fold change and a false discovery rate (FDR) of less than 0.05 **(Table S2)**. We then applied gene set enrichment analysis (GSEA) (29) based on Kyoto Encyclopedia of Genes and Genomes (KEGG) (30) to examine altered pathways in MIA tumors **(Figure 1B)**. The most enriched up-regulated pathway in MIA is ABC-transporters which has an established tumor-promoting role in regulating cell survival, proliferation, migration, invasion, angiogenesis, and inflammation (31). In addition, widely studied cancer-associated pathways, such as Ras signaling and PI3K-AKT signaling (32), are also upregulated. Furthermore, MIA tumors exhibit stronger cytokine::cytokine-receptor interactions than adjacent tissues. One particularly overexpressed cytokine, *CXCL13*, encodes a chemokine that has been reported as a major B lymphocyte chemoattractant (33) **(Fig. S2)**. Another pathway showing significant enrichment in MIA tumors is mucin-type O-glycan biosynthesis. Many genes in the mucin family are over-expressed in MIA, especially *MUC21*, *MUC5B*, and *MUC4* **(Figure 1C)**, a phenomenon also observed in TCGA lung adenocarcinoma (LUAD) **(Fig. S3)**. Over-expression of mucin family proteins have been reported to contribute to the carbohydrate-enriched coating of cancer cells, which could promote integrin-mediated tumor growth and survival (34). In addition, overexpression and glycosylation of mucins, especially of MUC1, have been reported in multiple cancers and implicated to promote tumor metastasis and drug resistance (35,36). The overexpression of mucin family members likely accounts for the enrichment of mucin-type O-glycan pathway in MIA tumors.

MIA tumors harbor EGFR and Mucin gene mutations

We next sought to detect mutations in MIA tumors by comparing RNA-seq data between tumor and adjacent normal tissue using Varscan2 (37). Although this is less sensitive than mutation

calling from DNA-based approaches such as whole genome or whole exome sequencing, we

still managed to find approximately 70 (median) variants per tumor, most of which were

missense mutations **(Fig. S4A)**. The most enriched type of single nucleotide variants (SNV)

is C>T transition **(Fig. S4B)**, which is known to be a signature of mismatch repair deficiency

resulting in elevated microsatellite instability (MSI) (38). To computationally assess the MSI

level of these MIA samples, we applied MSIsensor (10) to compare the RNA-seq data between

tumor and normal. Although this is also less sensitive than DNA-based approaches, we indeed

observed higher MSI score in MIA tumors with higher CT transition rate (**Fig. S4C**).

EGFR was found to be mutated in 31% of the MIA samples **(Figure 1D)**, consistent with the

previous report of the prevalent *EGFR* mutations in progressive stages of lung

adenocarcinoma (13). *EGFR* mutations occur mainly at the mutational hotspot "L858R/M" (39)

(Figure 1E) in the kinase domain, in agreement observations in TCGA LUAD **(Fig. S4D)**.

EGFR is known to participate in the signaling of the RTK-RAS pathway (32). The gain-of-

function EGFR mutations primarily contributed to the oncogenic activation of the RTK-RAS

pathway. Another important gene in the RTK-RAS pathway, *KRAS*, is mutated in only two

tumors (**Fig. S4E**), and as expected, occurs mutually exclusively with *EGFR* mutations (40).

In addition to RTK-RAS pathway mutations, *MUC6* and *MUC4* genes were also highly mutated

in MIA tumors. These two genes, as well as other MUC family members *MUC16*, *MUC5B* and

MUC17, are frequently mutated in TCGA LUAD **(Fig. S3)**. Most of the MUC family SNVs are

missense mutations, and together with their frequent over expression, suggest that tumor-

associated mucins might create neoantigens in MIA tumors. We therefore applied OptiType

(41) to infer the patient MHC Class I type and pVAC-Seq (42) to predict the likely neo-antigens

in these MIA tumors. Indeed, our analysis supports mutated MUC6, MUC4, MUC20 as being

potential neoantigens in MIA tumors (Fig. S5).

Higher B cell and CD4+ T cell infiltration and activation but lower CD8+ T cell infiltration

in MIA tumors

To decipher immune cell infiltration in the MIA TME, we estimated the immune cell composition

from bulk tumor RNA-seq data using TIMER (43), CIBERSORT (11). Relative to adjacent

normal tissues, MIA samples have significantly higher B cells and CD4+ T cells, and

significantly lower CD8+ T cells and macrophages **(Figure 2A and Fig. S6)**. Consistent with

the observation in MIA, TCGA LUAD tumors also showed higher B-cell and lower CD8+ T cell

infiltration in tumors than the adjacent normal tissues. Interestingly, B cell infiltration gradually

decreases towards normal during tumor progression from Stage I to Stage IV **(Figure 2B)** in

TCGA LUAD, suggesting that increased B cell increase is associated with early LUAD onset.

Next we characterized the immune repertoires in these samples to investigate the activation
and clonal expansion of tumor-infiltrating B and T cells. We ran TRUST, a computational
algorithm we developed (44,45), to assemble the T-cell and B-cell receptor (TCR and BCR)
repertoires from RNA-seq data. Significantly higher fractions of raw reads were mapped to
TCR and BCR in MIA tumors than normal tissues (**Fig S7A-B**). Consistent with this
observation, TRUST assembled significantly higher number TCR and BCR unique clonotypes
of Complementary Determining Region 3 (CDR3) sequences in MIA tumors (**Figure 2C-D**).
Since TRUST has better power to call the abundant and clonal-expanded TCRs and BCRs,
the fact that TRUST assembled more TCR/BCR clonotypes already suggest that T cells and
B cells have clonal expansion in the MIA tumors. Based on the CD4+ and CD8+ T cell
infiltration trend in MIA vs adjacent normal, we expect most of the T cell activation and clonal
expansion to occur in CD4+ T cells. Indeed, MIA tumors have significantly higher expression
of CD4+ T cell activation markers CD69, CD40LG, CD25 (IL2RA), and CD62 (SELL) (46-
49)(**Figure 2E**). However, since TCR diversity and clonality calculation could be confounded
since we couldn't distinguish TCRs from CD4+ vs CD8+ T cells, we turned to BCR to further
evaluate immune cell clonal expansion. For B cells, we not only observed higher total number
of BCR CDR3 clonotypes (**Figure 2D**) and BCR clusters (**Figure 2F**), but also lower BCR
diversity (**Figure 2G**) and higher BCR clonality (**Figure 2H**) in MIA than adjacent normal, which
strongly support B cell clonal expansion. In addition, B cells, upon antigen recognition and
clonal expansion, undergo somatic hype-mutation (SHM) to evolve BCRs with better antigen
binding affinity, and class-switch recombination (CSR) to transition to antibody-producing
plasma cells. Indeed, we also observed higher BCR SHM rate (**Figure 2I**), higher CSR (**Fig
S7C**) in MIA than adjacent normal, further supporting higher activated and clonal expanded B
cells.
222
To check whether the activated tumor-infiltrating B and T cells could generate more diverse
clonotypes for binding to different antigens in the TME, we compared the clonotypes detected
between tumors and adjacent normal tissues. Majorities of the BCR (58.6%, **Figure 3A**) or
TCR (57.8%) clonotypes were uniquely detected in tumors (**Figure 3B**), suggesting more B
cell and T cell infiltration and clonal expansion in MIA tumors. We measured the repertoire
similarity between each pair of MIA and adjacent tissue using Jaccard index (50,51), and found
within-individual repertoire similarity to be much higher than the across-patient repertoire
similarity (**Figure 3C**). Interestingly, the TCR and BCR similarities between tumor and normal
(**Figure 3C**) are correlated, suggesting that T cells and B cells have coordinated clonal
expansion in the MIA tumors. In addition, repertoire similarities among normal samples (N-N)
are higher than that among MIA samples (T-T) from differential patients (**Figure 3D**),
suggesting that tumor-specific antigens stimulate the expansion of different TCR and BCR

clones in different tumors. Furthermore, tumors with higher mutation burden, as inferred from

Varscan2, have significantly lower BCR (p-value < 0.01) and TCR (p-value < 0.001) repertoire

similarity between tumor and adjacent tissues (**Fig. 3E**). Collectively, these observations

suggest that TRUST-inferred immune receptor repertoires represent activated and clonal

expanded B cells and potentially CD4+ T cells for recognizing and binding to tumor antigens

in MIA.

Mucin mutation and overexpression is associated with CD4+ T cell-mediated B cell

activation in MIA tumors

Since B cells could be activated by direct antigen stimulation and interaction with CD4+ T cells,

we further checked how B cell activation was induced in MIA. It has been reported that MUC1

glycosylated peptides can induce MHCII-restricted B-T cell interactions (52). In addition, a

synthetic peptide from the MUC1 tandem repeat region was shown to be presented by MHCII

molecules which resulted in the initiation of T helper cell responses (53). In our MIA samples,

we observed a positive association between mucin level and MHCII level (**Figure 4A**), raising

the possibility that higher mucin expression in cancer cells might be associated with higher

MHCII presentation. In addition, CD40 and its ligand CD40L are well-known to mediate the

interaction between B cells and CD4+ T cells (54). We observed significant positive correlation

between CD40 and CD40L in MIA tumors **(Figure 4B)**, which suggests CD4+ T cell-mediated

B cell activation. The average level of CD40 and CD40L is associated with mucin expression

(**Figure 4C**). Furthermore, we observed MIA tumors with over-expressed mucins have higher

levels of IgG and IgA isotypes, suggesting higher level of B cell activation and transition to

plasma cells (**Figure 4D**). Taken together, these results implicate the potential interactions

between the mutation or overexpression on mucins, MHCII presentation to CD4+ T cells, and

B cell activation and plasma cell transition in MIA tumors.

To further investigate B cell activation among heterogeneous tumors, we characterized the

overall immune status among the MIA samples using five signatures derived from the TCGA

pan-cancer study (12).   These signatures include "IFN-g" (representing IFN-g response),

"Lymphocyte" (representing overall lymphocyte infiltration by B and T cells), "Macrophage"

(representing the activation of macrophages/monocytes), "TGF-β" (representing TGF-β

response), and "Wound healing" (representing core serum response). These five signatures

seem to have correlated signals in the MIA tumors, so we used the average of the five to rank

the MIA tumors from "immune-low" to "immune-high" **(Figure 4E, Methods)**. The "immune-

high" tumors are associated with increased expression of MHCII (**Fig. S8A**) and mucins (**Fig.**

S8B). In addition, the "immune-high" tumors are also associated with increased expression of

CD40 (**Fig. S8C**) and CD40L (**Fig. S8D**), suggesting stronger interactions between B cells

and CD4+ T cells. Furthermore, "immune-high" tumors are associated with higher B cell

signals, such as IgG and IgA expression (**Fig. S8E-F**) and unique BCR clonotypes (**Fig. S8H**).

Collectively, our observations suggest that mucin expression is associated with CD4+ T cell-

mediated B cell activation in MIA adaptive immunity.

Formation of tertiary lymphoid structure (TLS) in MIA tumors

Previous literature (18) reported that B-cell and CD4+ T-cell aggregation could lead to the

formation of tertiary lymphoid structures (TLS). TLS starts from scattered B and T cell

aggregation, progresses to follicles with separate T-Zones and B-Zones, and finally matures

into ectopic germinal centers (EGC) with follicular dendritic cells (FDC) in the light-Zone for

better B cell activation (20) (**Figure 5A**). In the EGC of mature TLS, B cells activates somatic

hypermutations, isotype class-switches, and antibody production(19). So far our analysis

revealed higher B-cell and CD4+ T-cell infiltration, lower CD8+ T-cell infiltration **(Figure 2A)**,

and higher CD4+ T cell-mediated B cell activation **(Figure 3, Figure 4)** in MIA tumors. This

motivated us to examine the expression of typical TLS markers for evidence of TLS formation

in MIA. CD19 and MS4A1 (CD20), which are typical B-cell markers (55,56), were highly

expressed in MIA tumors. The ligand-receptor pair CXCL13 and CXCR5, which are

conventional indicators of follicles (57), were also significantly higher expressed in MIA tumors.

Furthermore, the ligand-receptor pair CCL19 and CCR7, which are important for promoting T

cell and B cell homing to lymphoid structures (58), were also highly expressed in tumors

(Figure 5B). These six TLS markers were all positively correlated with TIMER-estimated B

cell and CD4+ T cell abundance but negatively correlated with CD8+ T cell abundance **(Figure**

5B).

Besides the six TLS markers we evaluated above, another 12-chemokine gene signature has

also been proposed to predict the presence of TLS (59,60). We observed highly correlated

expression signals between our six TLS markers and the 12-chemokine signatures **(Fig. S9A)**.

As a result, the two approaches give concordant TLS predictions in MIA tumors, and found

TLS signals to be associated with immune-high tumors with stronger CD4+ T cell mediated B

cell activation **(Fig. S9B-C)**. To further confirm the presence of aggregated B cells and CD4+

T cells in non-small-cell lung cancer (NSCLC), we also examined two recently published

NSCLC single-cell RNA-seq datasets with tumors and adjacent normal tissues (61,62). Indeed,

NSCLC tumors have higher level of MS4A1+ B cells, CD4+CXCR5+ follicular helper T cells

(Tfh) than adjacent normal tissues (**Fig. S10A-B, Fig. S11A-B**). In addition, we used a

computational algorithm CellPhoneDB (63) infer cell–cell communication from combined

expression of multi-subunit ligand–receptor complexes to confirm the interaction between

CD40LG in CD4+ T cells with CD40 in B cells (**Fig. S11C**). Collectively, our MIA RNA-seq

data and NSCLC scRNA-seq data support TLS formation in lung adenocarcinoma (**Figure 4**).

With the transcriptome evidences of TLS formation in MIA tumors, we next sought to confirm

TLS formation from pathology imaging. Firstly, we examined the hematoxylin and Eosin

staining (H&E) pathology slides and observed lymphocytes aggregation **(Fig. S12),** which

support TLS formation in MIA tumors. Then, we used a six-marker multiplex

immunohistochemistry (mIHC) to stain for TLS in 22 MIA tumors with high Tfh phenotype,

which included the markers CD20 for B cells, CD4 and CXCR5 for follicular helper T cells (Tfh),

CD8 for CD8+ T cells, and CD35 for follicular dendritic cells (FDC) **(Figure 5C)**. mIHC

confirmed the formation of TLS in MIA tumors, although different samples showed varying

level of TLS maturation **(Fig. S13)**. In the samples with mature EGC, we observed TLS B-cell

zone (TLS-BZ) as marked by CD20, TLS T-cell zone (TLS-TZ) as marked by CD4, and EGC

light zone (EGC-LZ) as marked by CD20, CD4, CXCR5, and CD35 **(Figure 5C, Fig. S14, Fig.**

S15). Furthermore, we segmented each observation field into different areas

(Adenocarcinoma tissue, Non-Follicle, TLS T zone, TLS B zone, EGC light zone) to quantify

and compare the immune cell density between TLS follicles and non-follicle areas. Here TLS

follicle area includes TLS-TZ, TLS-BZ, and EGC-LZ, and non-follicle area includes scattered

T cells and B cells outside of TLS. In MIA tumors, CD20+ B cells (**Figure 5D**, p-value < 0.0001),

CD4+ T cells (**Figure 5E**, p-value < 0.0001) and CD35+ FDC (**Figure 5F,** p-value < 0.0001)

were significantly higher in TLS than in non-follicular area. In contrast, CD8+ T cell showed

significantly lower density (p-value < 0.0001) in TLS follicles than in non-follicle areas **(Figure**

5G).

Treg recruitment as potential mechanism of CD8+ T cell exclusion in tertiary lymphoid

structures

Our transcriptome and mIHC data indicated that MIA tumors had lower CD8+ T cell infiltration

(**Figure 2A**) and lower CD8+ T cell density in TLS (**Figure 5G**), respectively. In addition, MIA

tumors have lower PD-L1 (CD274) expression than adjacent normal, suggesting PD-L1

independent mechanisms for CD8+ T cell suppression **(Fig. S16)**. This prompted us to explore

the potential mechanism of CD8+ T cell exclusion in TLS and MIA. We examined immune

suppressive cells, such as Tregs, M2 macrophages, neutrophils, monocytes, and fibroblasts

(64) for possible cause of CD8+ T cell exclusion. Most suppressive cells were lower in MIA

tumors than adjacent normal, with the exception of Treg cells (**Figure 6A**), suggesting a Treg-

mediated CD8 T cell exclusion. From two independent scRNA-seq datasets, we also observed

CD4+CXCR5+FOXP3+ follicular T regulatory (Tfr) cells to be enriched in NSCLC tumors (**Fig.**

S10B, Fig. S11B). These data suggest that Treg cells might be responsible to suppress CD8+

T cell infiltration in the region of lymphocyte aggregations **(Figure 4)**. To quantify the degree

of immune suppression over immune stimulation, we measured the ratio of follicular regulatory

T cells (Tfr) to follicular helper T cells (Tfh) in TLS by the normalized expression of three pairs

of phenotype markers for Tfr and Tfh cells (FOXP3 over BCL6, PDCD1 over ICOS, and IL2RA

over IL7R) (65), respectively. For each pair of markers, the ratio of Tfr / Tfh was negatively

associated with CD8+ T cell infiltration **(Figure 6B)**, suggesting that Tfr in TLS might have

negative effects on CD8+ T cell infiltration in MIA.

To further quantify the Tfr and Tfh in TLS, we used seven-marker mIHC staining on sequential

slides of 22 MIA samples with high TLS expression markers. Specifically, we used CD3, CD4,

CXCR5, and FOXP3 to detect Tfr cells and CD3, CD4, CXCR5, and BCL-6 to detect Tfh cells

(Figure 6C), respectively. Within the 69 available observation fields from the 22 MIA tumors,

we found lower CD8+ T cell density in TLS follicles than non-follicular areas **(Figure 6D,** $P <$

0.0001**)**, which was consistent with our observations in the six-plex mIHC panel **(Figure 5E)**.

In addition, we observed a higher ratio of regulatory T cells to helper T cells in TLS follicles

than in non-follicular areas **(Figure 6E,** $P = 0.0032$**),** indicating stronger immune suppression

mediated by Tfr cells in TLS. To determine how the balance between immune suppression

from Tfr and immune stimulation from Tfh influence CD8+ T cell infiltration in TLS, we split all

the observation fields into two groups based on the Tfr / Tfh ratio. While higher Tfr / Tfh ratio

was associated with lower CD8+ T cell density in TLS follicles **(Figure 6F)**, no such difference

was found in non-follicular areas **(Fig. S17)**. These results suggest TLS formation to be

associated with CD8+ T cell exclusion through Tfr mediated immune suppression.

Discussion

In this study, we characterized the tumor microenvironment (TME) of minimally invasive adenocarcinomas (MIA) by integrating transcriptome data (molecular profiling, mutation analysis, immune cell estimation, and immune repertoire inference) and pathology staining (hematoxylin and eosin staining and multiplex immune-histochemistry). We observed varying levels of TLS formation, from the initial T cells and B cell aggregates, to follicle formation, to the mature ectopic germinal centers (EGC), in the MIA TME. Furthermore, we propose follicular Treg (Tfr) cells in the TLS as a potential CD8+ T cell exclusion mechanism in MIA tumors.

Our analysis revealed mucins in MIA samples to be highly mutated, over-expressed, and highly glycosylated. Mucins synthesized by epithelial cells are well-known to undergo glycosylation alterations during neoplasia (66-68). Aberrant glycosylation metabolism is common in cancers and known to facilitate cell survival and proliferation (66). Mucin overexpression may promote tumorigenicity and metastasis (66), which was proposed as an independent predictor for poor prognosis in lung adenocarcinoma (34). Glycosylated tumor-associated mucin peptides have been reported be bound by MHCII molecules and presented by B cells, leading to the activation of CD4+ T cells which in turn activates B cells through CD40-CD40L interactions (52,69). Our study identified higher tumor-infiltrating B cells and CD4+ T cells in both MIA and TCGA lung adenocarcinoma. Moreover, MIA tumors exhibited strong signals of B cell activation, somatic hyper-mutation and clonal expansion. Our observation of the positive associations of mucins with MHCII, B cell activation, and CD40-CD40L interactions potentially suggested mucin overexpression as a potential cause of CD4+ T cell-mediated B cell activation in MIA tumors. In addition, this CD4+ T cell-mediated B cell activation seemed to be associated with "immune-high" tumors.

Our observation of tumor-infiltrating B and CD4+ T cells suggested lymphocyte aggregation and TLS formation in the MIA TME. We therefore examined additional transcriptome and pathology evidences of TLS formation in MIA tumors. From MIA transcriptome, we observed up-regulation of six key TLS indicators (19,70) of B cell infiltration (CD19, CD20), follicle phenotype (CXCR5, CXCL13), and lymphocyte homing (CCR7 and CCL19). The results were corroborated using another 12-chemokine TLS signature (59,60). From pathology, we not only observed lymphocyte aggregation in the H&E slides, but also confirmed the co-localization of B cells, Tfh and FDC in TLS using six-panel mIHC. EGC are known to activate B cells for somatic hypermutation, antibody affinity maturation, class switching, and antibody production (71). We observed higher density of CD20+ B cells, CD4+ T cells, and CD35+ FDC, but lower

density of CD8+ T cells in TLS follicles than in non-follicular areas. This motivated us to
investigate whether cells previously reported to suppress CD8 T cell infiltration, such as Tregs,
M2 macrophage, neutrophils, monocytes, or fibroblasts (64), inhibit CD8+ T cell infiltration in
MIA. Further examination of bulk RNA-seq on our MIA tumors implicated Treg as the culprit
of CD8 T cell exclusion in MIA tumors. This hypothesis was supported by previous auto-
immune studies in human and mouse (72-76). Using mIHC to evaluate the ratio between
immune suppression (Tfr) and immune stimulation (Tfh), we found a negative association
between the Tfr / Tfh ratio and CD8+ T cell infiltration, further supporting Tfr-mediated CD8+
T cell exclusion in MIA.

Controversy still exists regarding the impact of TLS on clinical prognosis. For example, TLS
was reported to be associated with poor prognosis in human hepatocellular carcinoma (77)
but good prognosis in colorectal cancer and breast cancer (78,79). In NSCLC cohorts, TLS in
the tumors was observed to be associated with favorable prognosis (80-82), dependent on
high CD8+ T cell and mature dendritic cell infiltration in the tumors, although we observed a
negative association between TLS with CD8 T cell infiltration in MIA tumors. Intriguingly,
recent studies also reported TLS to be associated with better response to immune checkpoint
inhibitors in melanoma and sarcoma (21,22,24). These studies suggest that the discrepancies
of TLS on clinical prognosis may be dependent on the cancer type and clinical contexts. Our
observation that TLS formation could be associated with Tfr recruitment, CD8 T cell exclusion,
and immune suppression have potentially important implications in cancer immunotherapy:
while tumors with TLS and a predominant Tfh recruitment might directly respond to anti-PD1
treatment, those with TLS and a predominant Tfr recruitment might benefit from initial anti-
CTLA4 treatment to deplete the Tregs before responding to anti-PD1 treatment. Our current
study is still limited in sample size and statistical power, although another study on medRxiv
reported similar findings in early lung cancers (83). Currently, our analysis only revealed
associations without having functional validation of the causal effects. Therefore, future
research and clinical studies are needed to fully elucidate the mechanism of CD8 T cell
exclusion and explore better immunotherapy strategies in cancer.

Methods

Sample collection and RNA sequencing

All 118 samples were collected from 59 MIA patients at Pulmonary Hospital, Shanghai, China. All specimens were obtained from patients with appropriate consent from the relevant institutional review board. The clinical information of these patients was shown in **Table S**1. The RNA extraction procedure was compiled with standard protocols. DNA and RNA were collected from samples using AllPrep DNA/RNA Mini Kit (Qiagen, 80204, Germany). The cDNAs were synthesized and used to construct RNA libraries using NEBNext Ultra RNA Library Prep Kit (NEB, E7530, USA) and NEBNext Multiplex Oligos for Illumina (NEB, E7335, USA). The libraries were sequenced on the Illumina HiSeq2500 platform via a 2x150bp paired-end sequencing at Annoroad Gene Technology (Beijing, China). For each sample, more than 100M fragments were sequenced.

Gene profile processing of MIA RNA-Seq data

The transcriptome data were processed by the standard RNA-Seq pipeline. We performed sequence mapping by STAR alignment (26), reads quantifying by HT-Seq Count (27), and gene expression measurement by TPM converting from read count. Differential expression analysis on paired samples was performed using edgeR (28). Gene set enrichment analysis was performed using GSEA (29). Pathway categories are referred from KEGG website(https://www.genome.jp/kegg/pathway.html)

TCGA data downloading

For TCGA LUAD dataset, we downloaded gene expression data and mutation data from firebrowse (http://firebrowse.org).

Mutation calling from paired RNA-Seq data

Mutation detection from paired RNA-Seq data was analyzed by Varscan2. Somatic variants from Varscan2 (37) were annotated by Variant Effect Predictor(VEP) (84) and vcf2maf (https://github.com/mskcc/vcf2maf). Variants with low quality were removed based on the criteria which GDC pipeline recommends (https://docs.gdc.cancer.gov/Data/File_Formats/ MAF_Format/). Mutation visualization was implemented by Maftools (85) and Complexheatmap (86).

Normalization for altered mucin expression

Z-score normalization of mRNA expression for patients was performed. One over-expressed or down-expressed gene was expected to have a difference of at least two standard deviations from the mean of expression in the reference samples.

Immune infiltration estimation from RNA-seq data

We applied Tumor IMmune Estimation Resource (TIMER) (43) to deconvolve the immune cell components in the TME using TPM expression data. To ensure robust abundance estimation, CIBERSORT (11) according to the predefined LM22 signature and XCELL (87) were both used to estimate immune cell infiltration.

The immune signature score for classifying "immune-low" and "immune-high" MIA tumors

From the pan-cancer paper (12), the immune signature data and the pre-trained scoring model were downloaded from the CRI-iAtlas (https://github.com/CRI-iAtlas/shiny-iatlas/). Based on the model, we computed the five representative immune signatures score from the expression data, which was normalized by paired normal tissues and median-centered by gene level. Then, we ranked MIA tumors from immune "low" to immune "high" based on the averaged immune signature score.

Definitions of BCR repertoire metrics

We applied TRUST3 to infer the immune repertoire from bulk RNA-seq data (44,45).We measured basic metrics to quantify immune repertoire and further performed paired comparison of TCR and BCR repertoire between tumor and tumor-adjacent tissues. The fraction of TCR or BCR reads was defined as the library size located in BCR loci, which is normalized by total mapped reads (E1). The number of unique TCR or BCR CDR3 sequences summarized the total unique CDR3 size. The number of TCR or BCR clonotypes per kilo reads measures TCR or BCR diversity. In addition, B cells undergo clonal expansions with a high rate of somatic hypermutation by single base substitutions in CDR3 sequences. Thus, we built BCR lineages referred to the method of a previous study (45), which generates 8-mer CDR3 motifs and an upper triangular matrix of counting the substitutions between DNA sequences from any two clonotypes in one BCR lineage to cluster partial and complete CDR3 sequences. For each sample, BCR or TCR clonality is defined by Shanno entropy (E2) (88). Somatic hypermutation rate was defined as the total count of harboring one base substitution normalized by the total length of aligned DNA sequence (E3). Ig class switch recombination (CSR) were built for the BCR clonotypes with different Ig isotypes from the same BCR lineage. Any two Ig isotypes within the same cluster motif could be switched based on the specific

506 order, which is IgM, IgD, IgG3, IgG1, IgA1, IgG2, IgG4, IgE, IgA2 (89,90). Here we only remain

507 the Ig isotypes with abundance more than 1% and check CSR on IgG and IgA for measuring

508 B cell activation signal. The ratio of CSR was computed referring to the method in the previous

509 study (45). The equations are shown below.

510
$$Fraction\ of\ TCR\ or\ BCR\ reads = \frac{l}{M} \qquad (E1)$$

511 l denotes library size located in BCR loci; M denotes total mapped reads.

512
$$Clonality = 1 - \frac{-\sum_{i=1}^{n} p_i log2(p_i)}{log2(n)} \qquad (E2)$$

513
$$p_i = \frac{f_i}{\sum_{i=1}^{n} f_i}$$

514 n denotes total number of TCR clonotypes or total number of BCR clusters and non-clustered

515 clonotypes, f_i denotes clonal frequency for non-clustered clonotypes or clustered clonotypes.

516
$$SHM\ rate = \frac{\sum_{i=1}^{c} S_i}{\sum_{i=1}^{c} \max(L_i)} \qquad (E3)$$

c denotes the number of BCR clusters, S_i denotes the sum of clonotype pairs harboring one

base substitution, L_i denotes the max number of aligned non-gapped DNA sequence in one

cluster.

Tumor purity evaluation

Tumor purity was estimated by the algorithm of EPIC (91) (http://epic.gfellerlab.org), which is

designed for estimating the absolute fraction of immune cells and cancer cells simultaneously

from RNA-seq expression data. We selected "tumor infiltrating cells" as reference profile to

predict cell fractions.

Single-cell RNA-seq data analysis

Two independent single-cell RNA-seq datasets were collected from NSCLC cohorts with

tumors and adjacent normal tissues (GSE139555, EMTAB6149). Single-cell RNA-seq dataset

pre-processing was performed by the comprehensive pipeline MAESTRO (92) . Single cell

clustering and cell type annotation are available to be visualized in TISCH (http://tisch.comp-

genomics.org/). In the dataset of NSCLC_ GSE139555, only cells from tumor and normal

tissues were extracted from raw count data for comparing gene expression of cells between

tumor and normal. In the dataset of NSCLC_ EMTAB6149, cluster averaged expression data

was downloaded from the paper supplementary data due to no available tissue information on

cell barcode level. Cell-cell interaction analysis was inferred utilizing a public method

CellPhoneDB (63). Only receptor-ligand pairs significantly enriched in less than 5% of all cell-

cell interactions were exhibited for the cell interactions on B cells or T cells in the dot plot.

Immunohistochemistry

Slides at 4-μm thickness were cut from paraffin blocks from MIA biopsies (n=59) and paired normal lung tissue. Slides were then stained for the interested markers in certain condition of antigen retrieval and incubation (**Table S3**) with Dako Real kit according to IHC-P protocol. Tonsil tissue were performed as control for staining optimization.

Multiplex immune-histochemistry staining for lymphocyte infiltrating in MIA

Twenty-two matched paraffin blocks of the 59 samples were processed through the 4-μm-thick section, deparaffinization in xylene, rehydration in an ethanol gradient. Slides were stained according to Opal 7-plex technology (PerkinElmer), yielding to the simultaneous visualization of seven markers (containing DAPI for nucleus) on the same slide. During each of the six cycles of staining, antigen retrieval (AR) was conducted via microwave treatment in AR solution pH 6 or pH 9 (AR6 or AR9) suggested by IHC validation; blocking was followed by instructions for 15 mins at room temperature (RT); and primary antibodies were then incubated for 1 hr at RT or overnight at 4 ℃. Next, HRP labeled polymer goat anti-mouse and rabbit antibodies were incubated at RT for 10 min followed by TSA opal fluorophores (Opal 520, Opal 540, Opal 570, Opal 620, Opal 650 or Opal 690) 10 min incubation. Microwave treatment was performed to remove the antibody TSA complex at each cycle of staining with AR solution (pH 9 or pH 6). Finally, all slides were counterstained with DAPI for 5 min and enclosed in ProLong Antifade Mountant (Solarbio). The slides were scanned using the PerkinElmer Mantra System, and the multispectral images obtained were unmixed using spectral libraries that were previously built from images stained for each fluorophore (mono-plex), using the inForm Advanced Image Analysis software (inForm 2.4.1 PerkinElmer).

Multispectral image analysis for tumor microenvironment of MIA

The entire area of the sections was stained, scanned, scored, and quantified. The scoring protocol consisted of several automated steps: tissue categorization, cell segmentation, and cell phenotyping. Using the integrated InForm image analysis software, multispectral images that were representative of different samples were selected and used to train the InForm software for categorization of the tissue into epithelium and stroma. Microinvasive epithelium without infiltration was tagged as "ACC" for cancer cell of adenocarcinoma, while lymphocyte infiltrating stroma area was further recognized as "Non-Fol", "TLS-BZ" and "TLS-TZ", representing scattered lymphocytes infiltration, B-cell zone of TLS formation, and T-cell zone of TLS formation. The settings learned from the training on the representative images from different samples were saved within an algorithm, which enabled a batch analysis of all the tissue slides. We designed six-plex TLS panel for TLS component cells and seven-plex Tfr/h

panel for suppressive/stimulatory immune cells. They were used on two sequential slides to characterize the immune microenvironment of MIA lesions. The TLS panel included CD4, CD8, CD20, CD35, DAPI, and CXCR5 while the Tfr/h panel included CD3, CD4, CD8, FOXP3, BCL-6, DAPI, and CXCR5. The software classified the tumor (epithelial) and infiltrated stromal regions. The classification was verified and approved by a certified pathologist (W.D.). For six-plex mIHC panel, CD20+ B density is defined as the percentage of CD20+ cells in total immune cells, including CD8+ cells, CD20+ cells, CD35+ cells, and CD4+ cells. Similarly, CD4+ T density is defined as the percentage of CD4+ cells in total immune cells. CD35+ density is defined as the percentage of CD35+ cells in total immune cells and CD8+ T density is defined as the percentage of CD8+ cells in total immune cells. For seven-plex mIHC panel, we defined the regulatory T-cell phenotype with $CD3^{+}CD4^{+}CXCR5^{+}FOXP3^{+}$Tfr and $CD3^{+}CD4^{+}CXCR5^{-}FOXP3^{+}$Treg and stimulatory T-cell phenotype with $CD3^{+}CD4^{+}CXCR5^{+}FOXP3^{-}$Tfh and $CD3^{+}CD4^{+}CXCR5^{-}FOXP3^{-}$Th. Either cell densities or absolute counts were enrolled for calculation.

Statistical analysis

For all the statistical test for comparing the difference between tumor and match adjacent tissues, Mann–Whitney U test was used to evaluate the P values and P< 0.05 was considered statistically significant. Multiple hypothesis correction was computed in the form of adjusted p-value through the Benjamini-Hochberg procedure. The thresholds used in the differential expression analysis were 2.0 for fold-change and 0.05 for the adjusted P value. Spearman's rank correlation coefficient was presented as the association of two independent features. A partial correlation test was used to measure the correlation between genes and immune cell infiltration when corrected by tumor purity. All the statistical tests were implemented using the R programming language.

Authors' Contributions

Conception and design: Jin Wang, Dongbo Jiang

Development of methodology: Jin Wang, Dongbo Jiang

Acquisition of data (acquired and managed patients, provided facilities): Peng Zhang, Gening Jiang, Fan Zhang, Wang Li, Tian Zhao

Analysis and interpretation of data (e.g., statistical analysis, computational analysis, experiment analysis): Jin Wang, Dongbo Jiang, Xiaoqi Zheng, Jian Zhang, Dongqing Sun, Zhe Zhang, Kun Yang

Writing and review the manuscript: Jin Wang, Dongbo Jiang, Ziyi Li, Kun Yang

Administrative, technical, or material support: Huansha Yu, Di Wang

Study supervision: Peng Zhang, Kun Yang

Data Availability

The RNA-seq data is deposited at Genome Sequence Archive (GSA), which is hosted by National Genomics Data Center (NGDC) under the submission code: subCRA003749. All the other data could be found at manuscript or available from the authors upon request.

Competing Interests

No competing interests.

Acknowledgments

The authors acknowledge Dr. X. Shirley Liu in Dana-Farber Cancer Institute and Dr. Arlene Sharpe in Harvard Medical School for the helpful discussion and advice, to Drs. Jia Liang and Rongjian Su in Jinzhou Medical University, Mr. Wei Liu and fellows of the SKLBCE-PerkinElmer Center of Excellence, Beijing, China for their assistance on the mIHC experiments.

This work was supported by the National Natural Science Foundation of China (Grant No. 81872290, 81972172, and 81772763), the Shanghai Science and Technology Committee (No. 19XD1423200, 18140903900).

References

1. Pinsky PF. Assessing the benefits and harms of low-dose computed tomography screening for lung cancer. Lung Cancer Manag **2014**;3(6):491-8 doi 10.2217/LMT.14.41.

2. Vinayanuwattikun C, Le Calvez-Kelm F, Abedi-Ardekani B, Zaridze D, Mukeria A, Voegele C, *et al.* Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma. Sci Rep **2016**;6:31628 doi 10.1038/srep31628.

3. Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, *et al.* Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun **2015**;6:8258 doi 10.1038/ncomms9258.

4. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, *et al.* Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell **2017**;169(4):750-65 e17 doi 10.1016/j.cell.2017.04.014.

5. Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, *et al.* Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature **2019**;571(7766):570-5 doi 10.1038/s41586-019-1330-0.

6. Inamura K. Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. International Journal of Molecular Sciences **2018**;19(4) doi 10.3390/ijms19041259.

7. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, *et al.* Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med **2018**;24(5):541-50 doi 10.1038/s41591-018-0014-x.

8. Graw S, Meier R, Minn K, Bloomer C, Godwin AK, Fridley B, *et al.* Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples. Sci Rep **2015**;5:12335 doi 10.1038/srep12335.

9. Heyer EE, Deveson IW, Wooi D, Selinger CI, Lyons RJ, Hayes VM, *et al.* Diagnosis of fusion genes using targeted RNA sequencing. Nat Commun **2019**;10(1):1388 doi 10.1038/s41467-019-09374-9.

10. Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, *et al.* MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics **2014**;30(7):1015-6 doi 10.1093/bioinformatics/btt755.

11. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, *et al.* Robust enumeration of cell subsets from tissue expression profiles. Nat Methods **2015**;12(5):453-7 doi 10.1038/nmeth.3337.

12. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, *et al.* The Immune Landscape of Cancer. Immunity **2018**;48(4):812-30.e14 doi 10.1016/j.immuni.2018.03.023.

13. Wang C, Yin R, Dai J, Gu Y, Cui S, Ma H, *et al.* Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. Nat Commun **2018**;9(1):2054 doi 10.1038/s41467-018-04492-2.

14. Hennecke J, Wiley DC. T cell receptor-MHC interactions up close. Cell **2001**;104(1):1-4 doi 10.1016/s0092-8674(01)00185-4.

15. Heesters BA, van der Poel CE, Das A, Carroll MC. Antigen Presentation to B Cells. Trends in Immunology **2016**;37(12):844-54 doi 10.1016/j.it.2016.10.003.

16. Tscharke DC, Croft NP, Doherty PC, La Gruta NL. Sizing up the key determinants of the CD8+ T cell response. Nature Reviews Immunology **2015**;15(11):705-16 doi 10.1038/nri3905.

17. Coussens LM, Werb Z. Inflammation and cancer. Nature **2002**;420(6917):860-7 doi 10.1038/nature01322.

18. Corsiero E, Nerviani A, Bombardieri M, Pitzalis C. Ectopic Lymphoid Structures: Powerhouse of Autoimmunity. Front Immunol **2016**;7:430 doi 10.3389/fimmu.2016.00430.

19.   Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in
infection, cancer and autoimmunity. Nat Rev Immunol **2014**;14(7):447-62 doi
10.1038/nri3700.

20.   Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures
in the era of cancer immunotherapy. Nature Reviews Cancer **2019**;19(6):307-25 doi
10.1038/s41568-019-0144-6.

21.   Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S*, et al.* Tertiary
lymphoid structures improve immunotherapy and survival in melanoma. Nature
2020;577(7791):561-5 doi 10.1038/s41586-019-1914-8.

22.   Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R*, et al.* B cells and tertiary
lymphoid structures promote immunotherapy response. Nature **2020**;577(7791):549-
55 doi 10.1038/s41586-019-1922-8.

23.   Bruno TC. New predictors for immunotherapy responses sharpen our view of the
tumour microenvironment. Nature **2020**;577(7791):474-6 doi 10.1038/d41586-019-
03943-0.

24.   Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun CM, Calderaro J*, et al.* B cells
are associated with survival and immunotherapy response in sarcoma. Nature
2020;577(7791):556-60 doi 10.1038/s41586-019-1906-8.

25.   Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB*, et al.* The
2015 World Health Organization Classification of Lung Tumors: Impact of Genetic,
Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol
2015;10(9):1243-60 doi 10.1097/JTO.0000000000000630.

26.   Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S*, et al.* STAR: ultrafast
universal RNA-seq aligner. Bioinformatics **2013**;29(1):15-21 doi
10.1093/bioinformatics/bts635.

27.   Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput
sequencing data. Bioinformatics **2015**;31(2):166-9 doi 10.1093/bioinformatics/btu638.

28.   Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data. Bioinformatics
2010;26(1):139-40 doi 10.1093/bioinformatics/btp616.

29.   Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA*, et al.*
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci U S A **2005**;102(43):15545-50 doi
10.1073/pnas.0506580102.

30.   Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids
Res **2000**;28(1):27-30 doi 10.1093/nar/28.1.27.

31.   Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more
than just drug efflux pumps. Nature Reviews Cancer **2010**;10(2):147-56 doi
10.1038/nrc2789.

32.   Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC*, et al.* Oncogenic
Signaling Pathways in The Cancer Genome Atlas. Cell **2018**;173(2):321-37 e10 doi
10.1016/j.cell.2018.03.035.

33.   Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-
attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues,
selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med **1998**;187(4):655-60
doi 10.1084/jem.187.4.655.

34.   Lakshmanan I, Ponnusamy MP, Macha MA, Haridas D, Majhi PD, Kaur S*, et al.* Mucins
in lung cancer: diagnostic, prognostic, and therapeutic implications. J Thorac Oncol
2015;10(1):19-27 doi 10.1097/JTO.0000000000000404.

35.   Bouillez A, Adeegbe D, Jin C, Hu X, Tagde A, Alam M*, et al.* MUC1-C promotes the
suppressive immune microenvironment in non-small cell lung cancer.
Oncoimmunology **2017**;6(9):e1338998 doi 10.1080/2162402X.2017.1338998.

36.   Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M*, et al.* MUC1-C Induces PD-L1
and Immune Evasion in Triple-Negative Breast Cancer. Cancer Res **2018**;78(1):205-
15 doi 10.1158/0008-5472.CAN-17-1636.

37. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, *et al.* VarScan 2:
somatic mutation and copy number alteration discovery in cancer by exome
sequencing. Genome Res **2012**;22(3):568-76 doi 10.1101/gr.129684.111.
38. Harris RS. Cancer mutation signatures, DNA damage mechanisms, and potential
clinical implications. Genome Med **2013**;5(9):87 doi 10.1186/gm490.
39. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, *et al.* EGFR mutations in
lung cancer: correlation with clinical response to gefitinib therapy. Science
2004;304(5676):1497-500 doi 10.1126/science.1099314.
40. Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H, *et al.* Coexistence of EGFR with KRAS, or
BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation
profiling from 5125 Chinese cohorts. Br J Cancer **2014**;110(11):2812-20 doi
10.1038/bjc.2014.210.
41. Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType:
precision HLA typing from next-generation sequencing data. Bioinformatics
2014;30(23):3310-6 doi 10.1093/bioinformatics/btu548.
42. Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, *et al.* pVAC-Seq:
A genome-guided in silico approach to identifying tumor neoantigens. Genome Med
2016;8(1):11 doi 10.1186/s13073-016-0264-5.
43. Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, *et al.* Comprehensive analyses
of tumor immunity: implications for cancer immunotherapy. Genome Biol
2016;17(1):174 doi 10.1186/s13059-016-1028-7.
44. Li B, Li T, Wang B, Dou R, Zhang J, Liu JS, *et al.* Ultrasensitive detection of TCR
hypervariable-region sequences in solid-tissue RNA-seq data. Nat Genet
2017;49(4):482-3 doi 10.1038/ng.3820.
45. Hu X, Zhang J, Wang J, Fu J, Li T, Zheng X, *et al.* Landscape of B cell immunity and
related immune evasion in human cancers. Nat Genet **2019**;51(3):560-7 doi
10.1038/s41588-018-0339-x.
46. Ivetic A, Hoskins Green HL, Hart SJ. L-selectin: A Major Regulator of Leukocyte
Adhesion, Migration and Signaling. Front Immunol **2019**;10:1068 doi
10.3389/fimmu.2019.01068.
47. Gorabi AM, Hajighasemi S, Kiaie N, Gheibi Hayat SM, Jamialahmadi T, Johnston TP,
et al. The pivotal role of CD69 in autoimmunity. J Autoimmun **2020**;111:102453 doi
10.1016/j.jaut.2020.102453.
48. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol
2005;23:515-48 doi 10.1146/annurev.immunol.23.021704.115611.
49. Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe?
Immunol Res **1997**;16(1):59-70 doi 10.1007/BF02786323.
50. Thomas N, Best K, Cinelli M, Reich-Zeliger S, Gal H, Shifrut E, *et al.* Tracking global
changes induced in the CD4 T-cell receptor repertoire by immunization with a complex
antigen using short stretches of CDR3 protein sequence. Bioinformatics
2014;30(22):3181-8 doi 10.1093/bioinformatics/btu523.
51. Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV, Putintseva EV,
et al. VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires. PLoS Comput
Biol **2015**;11(11):e1004503 doi 10.1371/journal.pcbi.1004503.
52. Cai H, Degliangeli F, Palitzsch B, Gerlitzki B, Kunz H, Schmitt E, *et al.* Glycopeptide-
functionalized gold nanoparticles for antibody induction against the tumor associated
mucin-1 glycoprotein. Bioorg Med Chem **2016**;24(5):1132-5 doi
10.1016/j.bmc.2016.01.044.
53. Cai H, Chen MS, Sun ZY, Zhao YF, Kunz H, Li YM. Self-adjuvanting synthetic
antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from
tetanus toxoid. Angew Chem Int Ed Engl **2013**;52(23):6106-10 doi
10.1002/anie.201300390.
54. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for
cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature
1998;393(6684):480-3 doi 10.1038/31002.

55. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol **1998**;51(5):364-9 doi 10.1136/jcp.51.5.364.

56. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol **2012**;1(1):36 doi 10.1186/2162-3619-1-36.

57. Havenar-Daughton C, Lindqvist M, Heit A, Wu JE, Reiss SM, Kendric K, *et al.* CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A **2016**;113(10):2702-7 doi 10.1073/pnas.1520112113.

58. Kobayashi D, Endo M, Ochi H, Hojo H, Miyasaka M, Hayasaka H. Regulation of CCR7-dependent cell migration through CCR7 homodimer formation. Sci Rep **2017**;7(1):8536 doi 10.1038/s41598-017-09113-4.

59. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, *et al.* Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol **2011**;179(1):37-45 doi 10.1016/j.ajpath.2011.03.007.

60. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, *et al.* 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep **2012**;2:765 doi 10.1038/srep00765.

61. Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, *et al.* Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med **2018**;24(8):1277-89 doi 10.1038/s41591-018-0096-5.

62. Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, *et al.* Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature **2020**;579(7798):274-8 doi 10.1038/s41586-020-2056-8.

63. Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat Protoc **2020**;15(4):1484-506 doi 10.1038/s41596-020-0292-x.

64. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov **2018**;17(12):887-904 doi 10.1038/nrd.2018.169.

65. Xu B, Wang S, Zhou M, Huang Y, Fu R, Guo C, *et al.* The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus. Clin Immunol **2017**;183:46-53 doi 10.1016/j.clim.2017.07.004.

66. Tuccillo FM, de Laurentiis A, Palmieri C, Fiume G, Bonelli P, Borrelli A, *et al.* Aberrant glycosylation as biomarker for cancer: focus on CD43. Biomed Res Int **2014**;2014:742831 doi 10.1155/2014/742831.

67. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer **2009**;9(12):874-85 doi 10.1038/nrc2761.

68. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer **2004**;4(1):45-60 doi 10.1038/nrc1251.

69. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol **2000**;67(1):2-17 doi 10.1002/jlb.67.1.2.

70. Nerviani A, Pitzalis C. Role of chemokines in ectopic lymphoid structures formation in autoimmunity and cancer. J Leukoc Biol **2018**;104(2):333-41 doi 10.1002/JLB.3MR0218-062R.

71. Domeier PP, Schell SL, Rahman ZS. Spontaneous germinal centers and autoimmunity. Autoimmunity **2017**;50(1):4-18 doi 10.1080/08916934.2017.1280671.

72. Sage PT, Sharpe AH. T follicular regulatory cells in the regulation of B cell responses. Trends Immunol **2015**;36(7):410-8 doi 10.1016/j.it.2015.05.005.

73. Sage PT, Ron-Harel N, Juneja VR, Sen DR, Maleri S, Sungnak W, *et al.* Suppression by TFR cells leads to durable and selective inhibition of B cell effector function. Nat Immunol **2016**;17(12):1436-46 doi 10.1038/ni.3578.

74. Wing JB, Tekguc M, Sakaguchi S. Control of Germinal Center Responses by T-Follicular Regulatory Cells. Front Immunol **2018**;9:1910 doi 10.3389/fimmu.2018.01910.

75. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, *et al.* Foxp3
expressing CD4+CD25(high) regulatory T cells are overrepresented in human
metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J
Immunol **2004**;173(2):1444-53 doi 10.4049/jimmunol.173.2.1444.
76. Clement RL, Daccache J, Mohammed MT, Diallo A, Blazar BR, Kuchroo VK, *et al.*
Follicular regulatory T cells control humoral and allergic immunity by restraining early
B cell responses. Nat Immunol **2019**;20(10):1360-71 doi 10.1038/s41590-019-0472-4.
77. Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, *et al.* Ectopic lymphoid
structures function as microniches for tumor progenitor cells in hepatocellular
carcinoma. Nat Immunol **2015**;16(12):1235-44 doi 10.1038/ni.3290.
78. Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, *et al.* Occurrence of
tertiary lymphoid tissue is associated with T-cell infiltration and predicts better
prognosis in early-stage colorectal cancers. Clin Cancer Res **2014**;20(8):2147-58 doi
10.1158/1078-0432.CCR-13-2590.
79. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, *et al.* CD4(+) follicular
helper T cell infiltration predicts breast cancer survival. J Clin Invest **2013**;123(7):2873-
92 doi 10.1172/JCI67428.
80. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, *et al.* Long-
term survival for patients with non-small-cell lung cancer with intratumoral lymphoid
structures. J Clin Oncol **2008**;26(27):4410-7 doi 10.1200/JCO.2007.15.0284.
81. Remark R, Lupo A, Alifano M, Biton J, Ouakrim H, Stefani A, *et al.* Immune contexture
and histological response after neoadjuvant chemotherapy predict clinical outcome of
lung   cancer   patients.   Oncoimmunology   **2016**;5(12):e1255394   doi
10.1080/2162402X.2016.1255394.
82. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, *et al.* Presence of
B cells in tertiary lymphoid structures is associated with a protective immunity in
patients with lung cancer. Am J Respir Crit Care Med **2014**;189(7):832-44 doi
10.1164/rccm.201309-1611OC.
83. Dejima H, Hu X, Chen R, Zhang J, Junya F, Parra EC, *et al.* Immune evolution from
preneoplasia to invasive lung adenocarcinomas and underlying molecular features.
2020:2020.07.11.20142992 doi 10.1101/2020.07.11.20142992 %J medRxiv.
84. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, *et al.* The Ensembl
Variant Effect Predictor. Genome Biol **2016**;17(1):122 doi 10.1186/s13059-016-0974-
4.
85. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and
comprehensive   analysis   of   somatic   variants   in   cancer.   Genome   Res
2018;28(11):1747-56 doi 10.1101/gr.239244.118.
86. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in
multidimensional   genomic   data.   Bioinformatics   **2016**;32(18):2847-9   doi
10.1093/bioinformatics/btw313.
87. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity
landscape. Genome Biol **2017**;18(1):220 doi 10.1186/s13059-017-1349-1.
88. Sims JS, Grinshpun B, Feng Y, Ung TH, Neira JA, Samanamud JL, *et al.* Diversity and
divergence of the glioma-infiltrating T-cell receptor repertoire. Proc Natl Acad Sci U S
A **2016**;113(25):E3529-37 doi 10.1073/pnas.1601012113.
89. Kitaura K, Yamashita H, Ayabe H, Shini T, Matsutani T, Suzuki R. Different Somatic
Hypermutation Levels among Antibody Subclasses Disclosed by a New Next-
Generation Sequencing-Based Antibody Repertoire Analysis. Front Immunol
2017;8:389 doi 10.3389/fimmu.2017.00389.
90. Looney TJ, Lee JY, Roskin KM, Hoh RA, King J, Glanville J, *et al.* Human B-cell isotype
switching origins of IgE. J Allergy Clin Immunol **2016**;137(2):579-86 e7 doi
10.1016/j.jaci.2015.07.014.
91. Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous
enumeration of cancer and immune cell types from bulk tumor gene expression data.
Elife **2017**;6 doi 10.7554/eLife.26476.

92.　Wang CS, Dongqing. MAESTRO: Model-based AnalysEs of Single-cell Transcriptome
and Regulome. **2020** doi 10.5281/zenodo.3862813.
907
908

    FIGURE LEGEND

Figure 1. MIA tumors are characterized by highly mutated and over-expressed mucins,
cytokine::cytokine-receptor interactions, and EGFR mutations
(A) Representative HE images of MIA. Top at 4X magnification, scale bar 300 μm. Boxed area
of top image shown below (20x magnification, scale bar 50 μm). Lymphocyte infiltration
(dashed box, bottom) and MIA tumor cells (solid box, bottom) are shown. **(B)** Normalized
enrichment scores (x-axis) of tumor-upregulated KEGG pathways. Colors indicate different
KEGG pathway categories. Asterisks denote significance level (*** FDR < 0.001; ** FDR <
0.01; * FDR < 0.05; NS FDR > 0.05). **(C)** Alterations of mucin genes in MIA patients. Each bar
represents a MIA patient. Shown are mutation classifications, and expression status. Values
on the right indicate the proportion of patients in which the gene was either mutated or had
altered expression. **(D)** Most commonly mutated genes in MIA patients. Colors indicate variant
type. Shown are the proportion of tumors containing a mutation in the indicated gene (left);
total number of mutations in the indicated gene (right). **(E)** Schematic of the EGFR gene,
showing mutations (stick and ball markers) and protein domains (color blocks).

Figure 2. Higher B and CD4+ T cell infiltration and activation but lower CD8+ T cell
infiltration characterize MIA tumors
(A) Comparison of immune components between tumor (red) and adjacent normal tissue (blue)
in MIA. Immune Cell Abundance values (y-axis) were generated from TIMER. Significance
levels are indicated (*** P < 0.001; ** P < 0.01; * P < 0.05; ns P> 0.05). **(B)** Immune infiltration
among TCGA lung adenocarcinoma (LUAD) samples separated by clinical stage (colors).
Comparison of fraction of TCR reads **(C)** and fraction of BCR reads (**D**) between MIA tumor
and adjacent normal tissues. (**E**) Comparison of gene expressions on CD4+ T cell activation
markers (CD69, CD40LG, IL2RA, and CD62) between MIA tumor and adjacent normal tissues.
Comparison of the number of BCR clusters (**F**), BCR clonotypes per kilo reads **(G)**, BCR
clonality **(H), and** somatic hyper-mutation rate of BCR **(I)** between MIA tumor and adjacent
normal tissues. Asterisks denote significance on difference between MIA tumors and adjacent
normal tissues (*** P < 0.001; ** P < 0.01; * P < 0.05).

Figure 3.   *Tumor-infiltrating B cells and T cells are activated by tumor antigens in MIA*
(A) Normalized BCR clonotype frequency on patient level. Each dot represents a BCR
clonotype and the normalized clonotype abundance in tumor and adjacent normal tissue. The
three percentage values correspond to the overall percentage of tumor-specific clonotypes
(58.6% in BCR), normal-specific clonotypes (38.6% in BCR), and shared (2.86% in BCR)

clonotypes. **(B)** Normalized TCR clonotype frequency on patient level. **(C)** Jaccard similarity
of the BCR/TCR clonotypes between tumor and adjacent normal tissues. Shown are shared
clonotypes within each patient (dark brown for BCR, dark green for TCR) and average shared
clonotypes between tumors and unmatched normal samples (light brown for BCR, light green
for TCR). **(D)** Jaccard similarity of BCR and TCR repertoire among tumors (solid line) and
normal tissues (dashed line) shown in top (BCR) and bottom (TCR) panel, respectively. **(E)**
Jaccard similarity in groups with high (blue) and low (red) mutation load (*** $P < 0.001$; ** $P <$
0.01; * $P < 0.05$).

Figure 4. Mucin mutation and overexpression is associated with CD4+ T cell-mediated
B cell activation in MIA tumors
(A) The correlation between mucins and MHCII expression. **(B)** The correlation between
CD40 and CD40LG expression. **(C)** The correlation between mucins and averaged level of
CD40 and CD40LG. **(D)** The correlation between mucin expression with IgG (green) and IgA
(brown) expression in MIA patients. **(E)** MIA tumors (x-axis) ranked by immune-related
signature score (heatmap colors). The top bar shows the average immune signature score for
each patient. The bottom bars show the tumor purity, expression level of mucins, MHCII
molecules, CD40, CD40LG, IgG, and IgA.

Figure 5. Formation of tertiary lymphoid structure (TLS) in MIA tumors
(A) The schema of TLS formation. The first stage is B & T cell aggregation. The second stage
is follicle formation with T-Zone and B-Zone. The third stage is ectopic germinal center
formation with formation with follicular dendritic cell in light-Zone. **(B)** Hierarchical clustering
of Z-score normalized gene expression of B-cell infiltration markers (CD19, CD20), follicle
phenotype markers (CXCR5, CXCL13), and lymphocyte homing signal markers (CCR7 and
CCL19). Color of the top bar represents tumor (red) or adjacent normal (blue) tissue.
Correlations between expression levels from these six TLS markers and immune cell
abundance corrected by tumor purity are shown in the right bar. **(C)** Typical observation field
of MIA six-plex TLS panel staining. The merged-channel multispectral image was captured
after 5-cycle TSA staining and DAPI counterstain, revealing a classic lymphoid structure
residing in MIA stromal tissue. Single channels are shown for the area bounded by the white
rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green,
CD20: red, CD35: cyan. Tfh cells are highlighted with white arrows (lower right corner images).
(D) Paired comparisons of CD20+ B cell density, CD4+ T cell density **(E),** CD35+ follicle
dendritic cell density **(F)**, and CD8+ T cell density **(G)** between Non-Follicle (Non-Fol) and TLS
areas.

Figure 6. Treg recruitment as potential mechanism of CD8+ T cell exclusion in tertiary

lymphoid structures

(A) Comparison of immune suppressive cell infiltration estimated from XCELL between MIA

tumor and adjacent normal tissues (*** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$). **(B)** Plot of Tfr/Tfh

marker ratio vs CD8+ T cell infiltration. FoxP3, PDCD1, and IL2RA are markers of Tfr cells,

while BCL6, ICOS, IL7R are markers of Tfh cells. See text. **(C)** Typical observation field of

MIA 7-plex panel staining for Tfr and Tfh. Merged multispectral image was captured after 6-

cycle TSA staining and DAPI counterstain and reveals a mature TLS architecture. Single

channels are shown for the area bounded by the white rectangle. Fake colors are assigned

as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, FOXP3: red, BCL6: cyan and CD3:

orange. Sub-populations of CD4+ T-cells are highlighted by arrows (Tfr: red, Treg: purple, Th:

green and Tfh: cyan). **(D)** Paired comparison of CD8+ T cell density between Non-Follicle

(Non-Fol) and TLS areas. **(E)** Paired comparison of ratio of regulatory T cells to helper T cells

between TLS and Non-Follicle areas. **(F)** Comparison of CD8+ T cell density between groups

with high and low Tfr/Tfh ratio.

Figure S1. The workflow of data processing.

In this workflow, five sections were performed for analyzing transcriptome data and imaging data, including expression profiling EdgR and GSEA, mutation calling from Varscan2, estimating immune cell infiltration from TIMER and CIBERSORT, quantifying immune repertoire from TRUST3, and Morphological validation from H&E staining, multiplex IHC, multispectral imaging and spatial statistics.

Figure S2. Differential gene expression analysis.

Colors of dots represent the tumor up-regulated genes (red) and tumor down-regulated genes (blue). Top differentially expressed mucin family members, cytokines, and cytokine receptors are highlighted in Volcano plot.

Figure S3. Genetic alterations of mucin family members in TCGA LUAD.

Mutations and gene alterations in mucin family members are highlighted with different colors, including inframe mutation (pink inside), missense mutation (green inside), truncating mutation (blue inside), mRNA high expression (pink outside), mRNA low expression (blue outside), and no alterations (grey).

Figure S4. Mutation overview of MIA.

The summary of variants from MIA, including the number of different variant classifications and SNV classes for each patient (**A**) and the frequency of nucleotide changes (**B**). (**C**) Comparison of msi score between high and low CT transition. (**D**) The mutation loci in EGFR. (**E**) The mutation pattern of EGFR, KRAS and TP53 in MIA.

Figure S5. Neo-epitope prediction for top mutated genes.

(**A**) Mutation rate (dark blue bar) and neo-epitope rate (MHC-I bound, light blue bar) among 59 patients for top 15 mutate genes. (**B**) Neo-epitope binding affinity and gene expression for top 15 mutated genes in patients. Each dot represents a predicted neo-epitope in a patient. Epitopes predicted from MUC20 (green), MUC4 (yellow), and MUC6 (purple) are highlighted with text. The color of dot represents the types of gene expression changes, including up-regulation (red), down-regulation (blue) and no change (grey).

Figure S6. Immune infiltration estimation from CIBERSORT.

Comparison of Immune cell infiltration estimated from CIBERSORT ("Absolute" mode) between MIA tumor and adjacent normal tissues.

Figure S7. Immune repertoire metrics in MIA. Comparison of faction of TCR reads (**A**), faction of BCR reads (**B**) between MIA tumor and normal tissues. (**C**) The ratio of Ig class switch recombination between IgG and IgA in MIA tumor and normal tissues. (*** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$).

Figure S8. Association between molecules mediated B-CD4+ T activation and immune-related signature score.
Association between MHCII level (**A**), mucin level (**B**), CD40 level (**C**), CD40LG level (**D**), IgG level (**E**), IgA level (**F**), and percentage of tumor unique BCR clonotypes (**G**) with immune-related signature score. MIA tumors are divided into "immune-low" and "immune-high" groups based on the median immune-related signature score. (*** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$).

Figure S9. 6 TLS markers and a 12-chemokine signature for predicting TLS existence.
(**A**) Association between 6 TLS markers expression and a 12-chemokine signature score. (**B**) Association between 6 TLS markers expression and immune-related signature score. (**C**) Association between a 12-chemokine signature score and immune-related signature score. MIA tumors are divided into "immune-low" and "immune-high" groups based on the median immune-related signature score. (*** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$).

Figure S10. B, follicular T helper, and follicular T regulatory cells are enriched in NSCLC tumors in an independent single-cell RNA-seq dataset NSCLC_GSE139555. (**A**) (left) cell distribution in different tissues and each color represents a type of tissue (left), including blood, NAT (normal adjacent tissue), and tumor;(right) cell type annotation and each color represents a cell type. (**B**) Gene expressions for CD4, CXCR5, FOXP3, and MS4A1 are compared between tumor and NAT across different cell types. (*** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$).

Figure S11. B, follicular T helper, and follicular T regulatory cells are enriched in NSCLC tumors in an independent single-cell RNA-seq dataset NSCLC_EMTAB6149. (**A**) cell type annotations. Each color represents a cell type. (**B**) Cluster averaged signature expression comparison between tumor (red) and normal tissues (blue) of different cell types. (**C**) Receptor-ligand pairs enrichment of different cell-cell interactions. The dot color represents the expression level of the receptor-ligand pairs and the dot size represents the enrichment significance of interaction pairs.

Figure S12. Evidence of TLS presence from H&E staining. The red circles denote the inferred TLS B and T cell aggregation.

1069 **Figure S13. Different maturation level of TLS formation and corresponding CD8+ T cell**
1070 **infiltration.** TLS formation stained by CD4(green), CD20(red), and CD35(cyan) co-
1071 localization in the left panel and CD8+ T cell infiltration in the right panel from the same
1072 observation field are shown.

1073

1074 **Figure S14. Normal germinal center in tonsil and ectopic germinal center in MIA.**
1075 Normal germinal center in tonsil (**A**) and ectopic germinal center in MIA (**B**). T-cell zone, B-
1076 cell zone, dark zone, and light zone consist of GC in tonsil or EGC in MIA stained by
1077 immunofluorescence (left) and immunohistochemistry (right).

1078

Figure S15. Multispectral analysis for segmenting tissues, cells and phenotypes.
Segmentation for six-plex panel for TLS (**A**) and seven-plex panel for Tfr and Tfh (**B**). Each
observation field could be segmented into 5 tissue categories as adenocarcinoma tissue
(ACT), Non-Follicle area (Non-Fol), TLS T-cell area (TLS-T), TLS B-cell area (TLS-B) and light
zone of germinal center (EGC-LZ) in both six-plex panel (top) and seven-plex panel (bottom).
Five phenotypes were contained in six-plex panel, including CC (blue), CD8+ T (yellow), CD4+
T (green), CD20+ B (red), and CD35+ FDC (cyan). Seven phenotypes were contained in
seven-plex, including CC (blue), CTL (yellow), Th (green), Tfh (cyan), Treg (pink), Tfr (red),
and oLeu (black). ACC: Adenocarcinoma cancer cell; CC: cancer cell; Non-Fol: Non-follicular
area; CTL: cytotoxic T lymphocyte; Th: T helper; Tfh: follicular T helper; Treg: regulatory T-
cell; Tfr: follicular Treg; FDC: follicular dendritic cell; oLeu: other leukocyte.

1090

1091 **Figure S16. Down-regulated PD-L1 in MIA tumors.** Comparison of the expression of PD-L1
1092 (CD274) in tumor (red) and adjacent-normal (blue) samples (*** $P < 0.001$; ** $P < 0.01$; * $P <$
1093 0.05).

1094

1095 **Figure S17. The ratio of regulatory T to helper T and CD8+ T cell infiltration in Non-**
1096 **follicle areas.** CD8+ T cell comparison between groups with high (red) and low (blue) ratio of
1097 regulatory T to helper T.

Figure1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure S1

Figure S2

Figure S3

Figure S4

Figure S5

A

B

Figure S6

Figure S7

Figure S8

Figure S9

Figure S10

Figure S11

Figure S12

Figure S13

Figure S14

Figure S15

Figure S16

Figure S17